Protein Sciences' FluBlok fails to gain FDA advisers' support

11/19/2009 | Bloomberg

Protein Sciences failed to obtain endorsement from an FDA panel for its flu vaccine FluBlok and was asked to conduct more trials to prove the drug's safety and ability for mass production. FluBlok is produced from flu genes injected into an insect virus and grown in caterpillar ovary cells, a technique proven to be faster than developing flu vaccines from chicken eggs.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT